This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Options Trade Into Ziopharm's Sarcoma Drug Study Results

Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.

Dynavax Options Trade for Heplisav FDA Approval Decision

Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.

Alexza Pharma: Premium Selling Options Strategy

A new options trade for Alexza going into an FDA drug approval decision.

Amicus: Bullish Options Trade Into Clinical Trial Catalysts

Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.

Dynavax: Speculative Upside Options Trade

How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.

Exelixis: New Drug Approval Options Trade

Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.

Eli Lilly: Bearish Options Trade
Eli Lilly: Bearish Options Trade

11/01/12 - 10:01 AM EDT

Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.

Ziopharm: Options Trade for Phase III Data

How to play the high-risk release of results from Ziopharm's phase III study.

How to Hedge Profits in Sarepta Therapeutics

Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.

Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs